Therefore, Gadd45a expression in CML patients at different phases of the disease was determined to obtain a more complete assessment of a role for this potential tumor suppressor and possible diagnostic marker in a clinical setting. This evidence concerns the gene GADD45A and chronic myelogenous leukemia, BCR-ABL1 positive.